Skip to main content

Market Overview

Flex Pharma Falls After Salarius Pharma Merger Delay


Flex Pharma (NASDAQ: FLKS) shares are trading lower after the company announced more shareholder votes are required to complete its merger with Salarius Pharma despite “overwhelming support.”

According to Flex Pharma, additional shares must be voted in order to complete the planned merger with Salarius Pharmaceuticals, an epigenetic oncology company.

Flex Pharma has also adjourned the special meeting until July 12 in order to provide shareholders with more time to complete proxies and vote their shares.

“We are very pleased that the vast majority of shareholders who voted support the merger with Salarius, consistent with the recommendations of both leading, independent proxy advisory services ISS and Glass-Lewis,” said Flex Pharma CEO William McVicar.

Flex Pharma traded down 26.6% to 47 cents per share.

Related Links:

Aclaris Announces Positive Results From Alopecia Treatment Trial

Pfizer To Buy Array Pharma For $48/Share


Related Articles (FLKS)

View Comments and Join the Discussion!

Posted-In: Salarius PharmaM&A News Penny Stocks Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at